Stocks · News reference
RBC Capital analyst Arun Viswanathan maintains DuPont de Nemours (NYSE:DD) with a Outperform and lowers the price target from $176 to $160.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
DuPont has developed two generations of microplastic-targeted probiotic strains, including a lead ingredient, DePlastox™ PD01, which demonstrated significant reduction of microplastics in a peer-reviewed study.
DuPont has introduced AmberChrom™ SIL, a new reverse-phase chromatography silica gel designed to support the purification and manufacturing of peptide therapeutics, including GLP-1 receptor agonists.
DuPont Nutrition & Biosciences has entered into a partnership with Sedex to centralize data collection and improve transparency across its operations.